Publikationen

Diese Liste enthält wissenschaftliche Publikationen, die der Karl Landsteiner Privatuniversität für Gesundheitswissenschaften zugeordnet werden, bis zum 31.8.2022. Für einen aktuellen Überblick besuchen Sie bitte das KL-Forschungsinformationssystem KRIS.

https://kris.kl.ac.at/de/organisations/division-molecular-oncology-and-hematology

2022

Andere wissenschaftliche Beiträge 2022

Klaus Podar. ASH 2021 – Ausgewählte Highlights der American Society of Hematology (ASH) – Multiples Myelom. krebs:hilfe! 1/2022
Klaus Podar. Pomalidomid und Dexamethason als Backbone moderner Triplettherapie. JATROS Hämatologie & Onkologie 2/2022
Klaus Podar. Highlights vom EHA 2022 -Multiples Myelom. krebs:hilfe! 4/2022
Klaus Podar. Highlights vom EHA 2022 -Multiples Myelom. UNIVERSUM INNERE MEDIZIN 9/22 (Heftbereich Hämatologie) MedMedia Verlag
Sonia Vallet, Klaus Podar. Tumor-Kachexie: Auch der Knochen leidet mit. NUTRITION News 2022

2022
- Zeitschriftenartikel
  - D'Andrea, D., Shariat, S.F., Soria, F., Mari, A., Mertens, L.S., Di Trapani, E., Carrion, D.M., Pradere, B., Pichler, R., Filippot, R., Grisay, G., Del Giudice, F., Laukhtina, E., Paulnsteiner, D., Krajewski, W., Vallet, S., Maggi, M., De Berardinis, E., Álvarez-Maestro, M., Brönimann, S., Di Maida, F., van Rhijn, B.W.G., Hendricksen, K. & Moschini, M., 2022. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. European urology open science, 41, S.74-80.
  - Dieckmann, K.-P., Pokrivcak, T., Geczi, L., Niehaus, D., Dralle-Filiz, I., Matthies, C., Dienes, T., Zschäbitz, S., Paffenholz, P., Gschliesser, T., Pichler, R., Mego, M., Bader, P., Zengerling, F., Heinzelbecker, J., Krausewitz, P., Krege, S., Aurilio, G., Aksoy, C., Hentrich, M., Seidel, C., Törzsök, P., Nestler, T., Majewski, M., Hiester, A., Buchler, T., Vallet, S., Studentova, H., Schönburg, S., Niedersüß-Beke, D., Ring, J., Trenti, E., Heidenreich, A., Wülfing, C., Isbarn, H., Pichlmeier, U. & Pichler, M., 2022. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Therapeutic advances in medical oncology, 14, S.17588359221086813.
  - Leisch, M., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Kiesl, D., Vallet, S., Egle, A., Melchardt, T., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F., Drost, M., Greil, R. & Pleyer, L., 2022. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers, 14(10), S.2459 [pii].
  - Lind, J., Hellinger, R., Kudweis, P., Moll, H.P., Gattringer, J., Thell, K., Edtmayer, S., Gruber, C.W., Stoiber-Sakaguchi, D. & Kollmann, K., 2022. The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma. Biomedicine & Pharmacotherapy, 153.
  - Sunder-Plassmann, V., Aksoy, O., Lind, J., Pecherstorfer, M., Vallet, S. & Podar, K., 2022. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: An early 2022 glance into the future. Expert Opinion on Pharmacotherapy.
    Link
- Konferenzbeitrag
  - Ludwig, H., Melchardt, T., Sormann, S., Zojer, N., Andel, J., Hartmann, B., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Schreder, M., Ruckser, R., Bozic, B., Krauth, M.T., Petzer, A., Schmitt, C., Machherndl-Spandl, S., Agis, H., Fillitz, M., Pönisch, W., Knop, S., Paiva, B. & Greil, R., 2022. Presentation: S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL). In HemaSphere.
2021
- Zeitschriftenartikel
  - Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies. Blood, 138(Supplement 1), S.1598-1598.
  - Fan, F. & Podar, K., 2021. The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers, 13(10), S.2326.
  - Fan, F., Malvestiti, S., Vallet, S., Lind, J., Garcia-Manteiga, J.Manuel, Morelli, E., Jiang, Q., Seckinger, A., Hose, D., Goldschmidt, H., Stadlbauer, A., Sun, C., Mei, H., Pecherstorfer, M., Bakiri, L., Wagner, E.F., Tonon, G., Sattler, M., Hu, Y., Tassone, P., Jaeger, D. & Podar, K., 2021. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia.
  - John, L., Krauth, M.Theresa, Podar, K. & Raab, M.-S., 2021. Pathway-Directed Therapy in Multiple Myeloma. Cancers, 13(7), S.1668.
  - Lapidot, M., Case, A.E., Weisberg, E.L., Meng, C., Walker, S.R., Garg, S., Ni, W., Podar, K., Hung, Y.P., Carrasco, R.D., Knott, A., Gokhale, P.C., Sharma, S., Pozhitkov, A., Kulkarni, P., Frank, D.A., Salgia, R., Griffin, J.D., Saladi, S.V., Bueno, R. & Sattler, M., 2021. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British journal of cancer.
  - Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Fan, F., Zwickl-Traxler, E., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 138(Supplement 1), S.2644-2644.
  - Manrique, I., Greil, R., Andel, J., Sormann, S., Hartmann, B.L., Podar, K., Egle, A., Petzer, A., Zojer, N., Gunsilius, E., Ruckser, R., Bozic, B., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Schreder, M., Wang, S.-Y., Willenbacher, W., Krauth, M.-T., Tinchon, C., Fillitz, M., Melchardt, T., Knop, S., Paiva, B. & Ludwig, H., 2021. Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation. Blood, 138(Supplement 1), S.1669-1669.
  - Podar, K. & Leleu, X., 2021. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers, 13(20), S.5154.
  - Pozzi, S., Bari, A., Pecherstorfer, M. & Vallet, S., 2021. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers, 13(19), S.4978.
  - Singer, J., Le, N.-S., Mattes, D., Klamminger, V., Hackner, K., Kolinsky, N., Scherb, M., Errhalt, P., Kreye, G., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers, 13(17).
  - Stadlbauer, A., Kinfe, T.M., Eyupoglu, I., Zimmermann, M., Kitzwögerer, M., Podar, K., Buchfelder, M., Heinz, G., Oberndorfer, S. & Marhold, F., 2021. Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans. Clinical cancer research : an official journal of the American Association for Cancer Research.
    Link
  - Tremblay, G., Daniele, P., Breeze, J., Li, L., Shah, J., Shacham, S., Kauffman, M., Engelhardt, M., Chari, A., Nooka, A., Vogl, D., Gavriatopoulou, M., Dimopoulos, M.-A., Richardson, P., Biran, N., Siegel, D., Vlummens, P., Doyen, C., Facon, T., Mohty, M., Meuleman, N., Levy, M., Costa, L., Hoffman, J.E., Delforge, M., Kaminetzky, D., Weisel, K., Raab, M., Dingli, D., Tuchman, S., Laurent, F., Vij, R., Schiller, G., Moreau, P., Richter, J., Schreder, M., Podar, K., Parker, T., Cornell, R.Frank, Lionel, K., Choquet, S. & Sundar, J., 2021. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 21(1), S.993.
  - Zwickl, H., Zwickl-Traxler, E., Haushofer, A., Seier, J., Podar, K., Weber, M., Hackner, K., Jacobi, N., Pecherstorfer, M. & Vallet, S., 2021. Effect of cachexia on bone turnover in cancer patients: a case-control study. BMC Cancer, 21(1), S.744.
- Konferenzbeitrag
  - Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Poster: P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S83-S84.
    Link
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Poster: Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy – Update. In OeGHO Frühjahrstagung. 8.-10.4.2021. Online, S. 23-41.
  - Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Zwickl-Traxler, E., Fan, F., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Presentation: OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S19-S20.
    Link
  - Ludwig, H., Melchardt, T., Sormann, S., Schreder, M., Andel, J., Hartmann, B., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Zojer, N., Ruckser, R., Bozic, B., Krauth, M.Theresa, Petzer, A., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Fillitz, M., Pönisch, W., Knop, S., Paiva, B. & Greil, R., 2021. Poster: Time to best response correlates with outcome in the randomized comparison between KRD and KTD followed by K maintenance or observation (AGMT-MM02 TRIAL). In EHA 2021 Virtual Congress. 9.-17.6.2021. Online, S. 325729; EP971.
- Andere wissenschaftliche Beiträge
  - Podar, K., 2021. Highlights beim Multiplen Myelom. krebs:hilfe!, (2), S.42-43.
2020
- Zeitschriftenartikel
  - Lapidot, M., Case, A.E., Larios, D., Gandler, H.I., Meng, C., Tosic, I., Weisberg, E.L., Poitras, M.J., Gokhale, P.C., Paweletz, C.P., Podar, K., Salgia, R., Saladi, S.V., Griffin, J.D., Frank, D.A., Bueno, R. & Sattler, M., 2020. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers, 13(1).
  - Manrique, I., Greil, R., Andel, J., Sormann, S., Hartmann, B.L., Podar, K., Egle, A., Petzer, A., Zojer, N., Ruckser, R., Bozic, B., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Schreder, M., Krauth, M.-T., Tinchon, C., Fillitz, M., Melchardt, T., Paiva, B. & Ludwig, H., 2020. Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study. Blood, 136(Supplement 1), S.29-30.
    Link
  - Podar, K., Shah, J., Chari, A., Richardson, P.G. & Jagannath, S., 2020. Selinexor for the treatment of multiple myeloma. Expert opinion on pharmacotherapy, S.1-10.
    Link
- Konferenzbeitrag
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2020. Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. In Abstractband für die Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts. 9.-11.10.2020. Online.
  - Ludwig, H., Melchardt, T., Andel, J., Gunsilius, E., Sormann, S., Hinke, A., Hartmann, B.L., Podar, K., Willenbacher, W., Egle, A., Petzer, A., Zojer, N., Woll, E., Ruckser, R., Bozic, B., Schmitt, C.A., Machherndl-Spandl, S., Krauth, M.-T., Schreder, M., Agis, H., Tinchon, C., Fillitz, M. & Greil, R., 2020. Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). In Blood 136 (Suppl. 1). S. 27-29.
    Link
  - Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B.L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Fillitz, M., Paiva, B. & Greil, R., 2020. Poster: Carfilzomib in combination with either Rd or Td overcomes the negative impact of HR cytogenetics in NDMM. Interim efficacy analysis of combined data of KRd vs. KTd followed by K maintenance or control. In 25th Congress of the European Hematology Association (EHA). COVID-19 Online.
- Andere wissenschaftliche Beiträge
  - Podar, K., 2020. Multiples Myelom 2020 – was für Patienten erreicht wurde. krebs:hilfe!, (5), S.30-33.
  - Podar, K., 2020. Stellenwert der autologen Stammzelltransplantation beim multiplen Myelom. JATROS Hämatologie & Onkologie, (2), S.6-9.
  - Vallet, S., 2020. Kombinationstherapien in der Behandlung urogenitaler Tumoren. JATROS Hämatologie & Onkologie, (2).
2019
- Zeitschriftenartikel
  - Chari, A., Vogl, D.T., Gavriatopoulou, M., Nooka, A.K., Yee, A.J., Huff, C.A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., A. Stewart, K., Richter, J., Vij, R., Tuchman, S., Raab, M.S., Weisel, K.C., Delforge, M., Cornell, R.F., Kaminetzky, D., Hoffman, J.E., Costa, L.J., Parker, T.L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R.L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M.G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J.-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P.G. & Jagannath, S., 2019. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England journal of medicine, 381, S.727-738.
  - Li, S., Vallet, S., Sacco, A., Roccaro, A., Lentzsch, S. & Podar, K., 2019. Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert opinion on investigational drugs, 28, S.445-462.
    Link
  - Lind, J., Czernilofsky, F., Vallet, S. & Podar, K., 2019. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert opinion on emerging drugs, 24, S.133-152.
    Link
  - Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiss, A., Schulze-Bergkamen, H., Opferman, J.T., Cardone, M.H., Jager, D. & Podar, K., 2019. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast cancer research and treatment, 173, S.585-596.
    Link
- Konferenzbeitrag
  - Fan, F., Malvestiti, S., Shen, Y., Morelli, E., Mishima, Y., Seckinger, A., Hose, D., Bakiri, L., Vallet, S., Sattler, M., Roccaro, A.M., Goldschmidt, H., Percherstorfer, M., Sun, C., Hu, Y., Wagner, E.F., Tassone, P., Ghobrial, I.M., Jaeger, D. & Podar, K., 2019. Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2019. Poster: Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. In 17th International Myeloma Workshop. Boston.
  - Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Sattler, M., Bakiri, L., Wagner, E.F., Percherstorfer, M. & Podar, K., 2019. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Ludwig, H., Sormann, S., Zojer, N., Andel, J., Hartmann, B.L., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Woll, E., Ruckser, R., Bozic, B., Krauth, M.-T., Petzer, A., Schmitt, C.A., Machherndl-Spandl, S., Agis, H., Paiva, B. & Greil, R., 2019. Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Pleyer, L., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Petzer, A., Schmitt, C.A., Vallet, S., Mandac, I., Geissler, K., Sperr, W.R., Leisch, M., Egle, A., Melchardt, T., Fusinato, J., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F. & Greil, R., 2019. Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.
    Link
  - Podar, K., 2019. Multiples Myelom II. In DGHO, OeGHO, SGMO & SGH 2019 (Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie). Berlin.
  - Podar, K., 2019. Präsentation: Klinisch relevante Arzneimittelinteraktionen im Multiplen Myelom. In Hämatologie im Wandel der Zeit . 28.-29.06.2019. Wien.
  - Podar, K., 2019. Präsentation: Stellenwert der Autologen Stammzelltransplantation beim Multiplen Myelom. In 9. Niederösterreichischer Onkologietag. Krems.
  - Podar, K., 2019. Presentation: Targeting transcription factors for cancer therapy: evolving therapeutic strategies . In 9. Niederösterreichischer Onkologietag. Krems.
2018
- Zeitschriftenartikel
  - Breitkreutz, I., Podar, K., Figueroa-Vazquez, V., Wilhelm, S., Hayden, P.J., Anderson, K.C. & Raab, M.S., 2018. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Annals of Hematology, 97, S.839-849.
    Link
  - Podar, K., 2018. Choosing an appropriate salvage therapy for a patient with multiple myeloma. Expert Opinion on Pharmacotherapy, 19, S.1511-1516.
  - Vallet, S., Filzmoser, J.M., Pecherstorfer, M. & Podar, K., 2018. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10, S.202.
  - Vallet, S., Hoyle, N.R., Kyle, R.A., Podar, K. & Pecherstorfer, M., 2018. A role for bone turnover markers beta-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia & Lymphoma, 59, S.2431-2438.
    Link
- Konferenzbeitrag
  - Malvestiti, S., Fan, F., Bashari, H.M., Morelli, E., Seckinger, A., Hose, D., Goldschmidt, H., Zoernig, I., Bakiri, L., Sattler, M., Vallet, S., Pecherstorfer, M., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2018. Poster: Multiple myeloma pathogenesis: The role of JunB in bone marrow angiogenesis. In 23rd Congress of the European Hematology Association (EHA). Stockholm, Sweden.
  - Podar, K., 2018. Presentation: Transcription factors in multiple myeloma: new potential targets. In 4th Multiple Myeloma and related malignancies. Bari, Italy.
  - Podar, K., 2018. Therapiefortschritte – Hämato-Onkologie im Jahr 2018: Multiples Myelom. In 8. Niederösterreichischer Onkologietag. Krems.
- Andere wissenschaftliche Beiträge
  - Podar, K., 2018. Immunmodulierende Medikamente bleiben essenzielle Basis der Therapie. JATROS Hämatologie & Onkologie, (5), S.41.
  - Podar, K., 2018. Teamwork gegen Krebs. Gesund leben in Niederösterreich, (6), S.30-32.
  - Vallet, S., 2018. Checkpointblockade beim metastasierten Urothelkarzinom. JATROS Hämatologie & Onkologie, (2).
2017
- Zeitschriftenartikel
  - Bhanot, H., Weisberg, E.L., Reddy, M.M., Nonami, A., Neuberg, D., Stone, R.M., Podar, K., Salgia, R., Griffin, J.D. & Sattler, M., 2017. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget, 8, S.67639-67650.
  - Fan, F., Bashari, M.H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., Sun, C., Hu, Y., Ball, C.R., Glimm, H., Sattler, M., Goldschmidt, H., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2017. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 31, S.1570-1581.
    Link
  - Podar, K. & Jager, D., 2017. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Current Cancer Drug Targets, 17, S.782-805.
    Link
  - Podar, K. & Pecherstorfer, M., 2017. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy, 18, S.1061-1079.
    Link
  - Rosenberger, F., Wiskemann, J., Vallet, S., Haag, G.M., Schembri, E., Jager, D. & Grüllich, C., 2017. Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial. Support Care Cancer, 25, S.3655-3664.
    Link
  - Vallet, S., Pecherstorfer, M. & Podar, K., 2017. Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 17, S.1511-1522.
    Link

Informationen für

2022

Andere wissenschaftliche Beiträge 2022

2022

Zeitschriftenartikel

Konferenzbeitrag

2021

Zeitschriftenartikel

Konferenzbeitrag

Andere wissenschaftliche Beiträge

2020

Zeitschriftenartikel

Konferenzbeitrag

Andere wissenschaftliche Beiträge

2019

Zeitschriftenartikel

Konferenzbeitrag

2018

Zeitschriftenartikel

Konferenzbeitrag

Andere wissenschaftliche Beiträge

2017

Zeitschriftenartikel

Aktuelles

12. Symposion Dürnstein

Wie erleben Kinder den Übertritt in die Unterstufe?

Allergien in Europa: Erstmals regionale Unterschiede in Sensibilisierungsprofilen bei Kindern festgestellt

Events

12. Symposion Dürnstein

INFO TALK: Bewerbung Medizinstudium

KL Luchtime Seminar: CaMKII spreads activity by inter-holoenzyme phosphorylation

Kontakt